Robert W. Baird reiterated their buy rating on shares of Align Technology, Inc. (NASDAQ:ALGN) in a research note published on Tuesday.

ALGN has been the topic of several other reports. Bank of America Corporation raised shares of Align Technology from a neutral rating to a buy rating and upped their target price for the stock from $175.00 to $193.00 in a research note on Friday, July 28th. Stifel Nicolaus reaffirmed a buy rating and set a $205.00 target price (up from $200.00) on shares of Align Technology in a research note on Monday, August 7th. Piper Jaffray Companies reaffirmed a buy rating and set a $200.00 target price on shares of Align Technology in a research note on Monday, September 11th. Credit Suisse Group reaffirmed an outperform rating and set a $170.00 target price (up from $140.00) on shares of Align Technology in a research note on Thursday, July 13th. Finally, Zacks Investment Research downgraded shares of Align Technology from a strong-buy rating to a hold rating in a research note on Monday, August 21st. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $179.82.

Shares of Align Technology (NASDAQ ALGN) traded down 0.19% during trading on Tuesday, reaching $184.50. 1,862,314 shares of the company traded hands. The firm’s 50 day moving average price is $175.22 and its 200-day moving average price is $143.46. The company has a market capitalization of $14.79 billion, a price-to-earnings ratio of 63.18 and a beta of 1.55. Align Technology has a 52 week low of $83.27 and a 52 week high of $186.10.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the consensus estimate of $0.73 by $0.12. Align Technology had a net margin of 19.18% and a return on equity of 23.87%. The firm had revenue of $356.50 million for the quarter, compared to analyst estimates of $343.43 million. During the same period in the prior year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 32.3% compared to the same quarter last year. Equities analysts anticipate that Align Technology will post $3.40 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/16/align-technologys-algn-buy-rating-reaffirmed-at-robert-w-baird.html.

Several large investors have recently made changes to their positions in ALGN. Schroder Investment Management Group purchased a new stake in shares of Align Technology in the 2nd quarter valued at approximately $104,000. CENTRAL TRUST Co increased its position in shares of Align Technology by 128.5% in the 2nd quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 392 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Align Technology by 6.9% in the 1st quarter. Van ECK Associates Corp now owns 1,057 shares of the medical equipment provider’s stock valued at $121,000 after purchasing an additional 68 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of Align Technology by 13.0% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock valued at $137,000 after purchasing an additional 105 shares during the last quarter. Finally, BlueMountain Capital Management LLC purchased a new stake in shares of Align Technology in the 2nd quarter valued at approximately $148,000. 81.72% of the stock is currently owned by institutional investors.

Align Technology Company Profile

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Stock Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related stocks with our FREE daily email newsletter.